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Abstract 
Review on t(10;14)(q24;q32) NFKB2/IGH, with 
data on clinics, and the genes involved. 
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Identity 
Note 
The t(10;14)(q24.31;q11) in T-ALL involves the 
gene TLX1 at the band 10q24.31 and not NFKB2 at 
band 10q24.32 (Neri et al., 1991). 
Conventional karyotype: Partial G and R banded karyotype. The derivative chromosomes are denoted with 
arrows. G-Banding, Courtesy Nathalie Nadal. R-banding, Courtesy Christine Lefebvre (upper row), N Nadal 
(lower row); FISH: top: WCP7R/WCP10G (aquarius); XL t(11;14)(IGH/CCND1) (metasystems) 
11q13R/14q32G - Courtesy Christine Lefebvre 
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Clinics and pathology 
Disease 
 B-cell lymphomas:   The band 10q24 is involved in 
7% of low-grade B-cell lymphomas, splenic 
marginal zone B-cell lymphomas in particular (Solé 
et al., 2001; Lefebvre et al., 2007, Nadal, 
unpublished observation) and also, but less 
frequently, in intermediate and high risk lymphomas 
(Neri et al., 1991).  
 
 Other chronic lympho proliferative diseases:   
Multiple myeloma (Migliazza et al., 1994; Mohamed 
et al.), chronic lymphocytic leukemia (CLL) 
(Migliazza, 1994) 
Prognosis 
Unknown. 
Cytogenetics 
Cytogenetics morphological 
The t(10;14)(q24;q32) is a rare but recurrent 
abnormality in lymphoid malignancies. 
Additional anomalies 
The following known recurrent abnormalities were 
found in one case each: +3, +7, and +12. 
Genes involved and 
proteins 
NFKB2 (nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
2 (p49/p100)) 
Location 
10q24.32 
Note 
Alias: LYT-10, NF-kB2, p105, p49/p100, p52 
DNA/RNA 
NFKB2 gene is a member of NFKB gene family. 
NFKB2 gene encodes for the precursor p100/p52 
from which the active p52 subunit is formed. 
Protein 
P52 is a member of the NFKB family transcription 
factors that are formed by the homo/dimerization of 
the subunits of the NFKB family. After dimerization 
with the subunit RELB, P52 migrates to the nucleus 
where they activate the transcription of target genes.  
 
Localization:  cytosol for p100 product and nucleus 
for the final product p52 after activation 
 
P52 is a component of the non-canonical NF-KB 
pathway which plays a role in the control of the last 
stages of B-Cells development (maintenance of the 
Germinal Center (GC) reaction and Plasma cell 
development) (Shaffer et al., 2012; De Silva et al., 
2017). 
IGH (Immunoglobulin Heavy chain) 
Location 
14q32 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
t(10;14)(q24;q32) translocation juxtaposes IGH 
constant region gene with NFKB2 gene (Neri et al., 
1991). The fusion gene NFKB2/IGH results in the 
constitutional activation of the non-canonical NFKB 
pathway. The reciprocal fusion gene IGH/NFKB2 is 
not transcribed. 
Fusion protein 
Note 
NFKB2 gene encodes for the protein P52 which 
contains a DNA binding domain and an Ankyrin 
domain. The Ankyrin domain is thought to retain 
p100/P52 in the cytoplasm and thus prevent the 
DNA binding.  
 
The band in 10q24 can be involved in different types 
of rearrangement such as cryptic deletion or 
translocation t(10;14). The common consequence is 
a truncated protein which retains the DNA binding 
domain but lack the Ankyrin domain (Migliazza et 
al., 1994). These rearrangements result in a 
constitutive activation of P52 which lead to the 
activation of the non-canonical NFKB pathway and 
thus promote B-cell malignancies (de silva, 2017; 
Guo, 2017). 
Expression / Localisation 
Nucleus. 
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